QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently today that it has expanded its relationship with BGI, the world’s largest genomics organization, to provide QIAGEN’s Ingenuity® Variant Analysis™ in integrated bioinformatics for all customers of BGI’s sequencing services.
Eli Lilly and Company (NYSE:LLY) and BioNTech AG recently announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body’s own immune system to attack cancer cells and create possible new treatment options for cancer patients.
Earlier this year MediSapiens announced a joint venture with International Cancer Advocacy Network (ICAN) to develop and publish Remission Coach®, a web-based solution that addresses the urgency of cancer management. This innovative solution provides cancer patients with a personalized platform for actively determine the most appropriate clinical trial for that patient’s disease and treatment history. Now MediSapiens announces collaboration with Genoscoper Laboratories, leading animal DNA diagnostics laboratory.
Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients
IBM Watson Health (NYSE: IBfM) recently announced that it is collaborating with more than a dozen leading cancer institutes to accelerate the ability of clinicians to identify and personalize treatment options for their patients. The institutes will apply Watson’s advanced cognitive capabilities to reduce from weeks to minutes the ability to translate DNA insights, understand a person’s genetic profile and gather relevant information from medical literature to personalize treatment options. The project is part of IBM’s broader Watson Health initiative to advance patient-centered care and improve health.
Cancer Treatment Centers of America® Global (CTCA) recently unveiled its new Centers for Advanced Individual Medicine, a resource that will make advanced genomic testing available to clinically qualified patients recommended by their physicians. The CTCA hospital-based Centers will provide patients and physicians with access to advanced genomic testing when recommended by a patient’s physician, and help educate patients about the potential benefits of precision cancer treatment.